
INTS
Intensity Therapeutics Inc
- Overview
- Forecast
- Valuation
- Earnings

Line
|

Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
0.3382
Open
0.330
VWAP
0.33
Vol
6.14M
Mkt Cap
8.47M
Low
0.31925
Amount
2.03M
EV/EBITDA(TTM)
--
Total Shares
13.71M
EV
7.55M
EV/OCF(TTM)
--
P/S(TTM)
--
Intensity Therapeutics, Inc. is a late-stage clinical biotechnology company. It is engaged in developing treatments that address both the regional and systemic nature of a patient’s cancer. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its lead product candidate, INT230-6, comprises three components: cisplatin, a proven anti-cancer cytotoxic agent, vinblastine sulfate, also a proven anti-cancer cytotoxic agent, and an amphiphilic molecule (SHAO) which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection. Its pipeline consists of INVINCIBLE-3 Study, a Phase 3 open-label, randomized study testing the superiority INT230-6 used as monotherapy compared to the standard of care drugs in 2nd and 3rd line treatment for certain soft tissue sarcoma subtypes, a Phase 2 clinical study in metastatic triple negative breast cancer.
Show More
3 Analyst Rating

1053.85% Upside
Wall Street analysts forecast INTS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for INTS is 3.75 USD with a low forecast of 3.50 USD and a high forecast of 4.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
1 Hold
0 Sell
Moderate Buy

1053.85% Upside
Current: 0.325

Low
3.50
Averages
3.75
High
4.00

1053.85% Upside
Current: 0.325

Low
3.50
Averages
3.75
High
4.00
Alliance Global Partners
Buy
downgrade
2025-05-22
Reason
Alliance Global Partners
Price Target
2025-05-22
downgrade
Buy
Reason
Alliance Global Partners lowered the firm's price target on Intensity Therapeutics to $3.50 from $8.50 and keeps a Buy rating on the shares. The price target reduction reflects the trial delay for INT230-6 for soft tissue sarcoma, the analyst tells investors in a research note. The trial is being paused until further notice due to funding constraints, and the firm believes it will take a major funding event to get it back on track.
Brookline
analyst
Buy -> Hold
downgrade
2025-05-19
Reason
Brookline
analyst
Price Target
2025-05-19
downgrade
Buy -> Hold
Reason
Brookline downgraded Intensity Therapeutics to Hold from Buy and suspended the firm's price target pending visibility into additional funding. A global Phase 3 open label, randomized, superiority trial is ongoing in metastatic sarcoma, evaluating INT230-6 monotherapy as an intratrumoral treatment compared to the standard of care in second and third line treatment in soft tissue sarcoma subtypes, notes the analyst, who points out that enrollment completion is expected in the first half of 2026, with data readouts expected based on the number of deaths in the trial.
Alliance Global Partners
James Molloy
Strong Buy
Initiates
$8.5
2025-01-13
Reason
Alliance Global Partners
James Molloy
Price Target
$8.5
2025-01-13
Initiates
Strong Buy
Reason
Alliance Global Partners initiated coverage of Intensity Therapeutics with a Buy rating and $8.50 price target. Intensity is developing INT230-6, a Phase 3 asset that both decreases the tumor burden while also activating an increased immune system response to better recognize and target the cancer, for advanced soft tissue sarcoma and triple negative breast cancer. The firm values INT230-6 for STS at $6 per share, INT230-6 for TNBC at $2 per share, and the remaining compounds and cash at 50c per share, the analyst noted.
HC Wainwright & Co.
Swayampakula Ramakanth
Strong Buy
Reiterates
$5
2024-11-21
Reason
HC Wainwright & Co.
Swayampakula Ramakanth
Price Target
$5
2024-11-21
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Swayampakula Ramakanth
Strong Buy
Initiates
$5
2024-10-31
Reason
HC Wainwright & Co.
Swayampakula Ramakanth
Price Target
$5
2024-10-31
Initiates
Strong Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for Intensity Therapeutics Inc (INTS.O) is -0.49, compared to its 5-year average forward P/E of -3.59. For a more detailed relative valuation and DCF analysis to assess Intensity Therapeutics Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A
5Y Average PE
-3.59
Current PE
-0.49
Overvalued PE
-1.26
Undervalued PE
-5.91
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financials
Annual
Quarterly
FY2025Q1
YoY :
-28.44%
-3.39M
Operating Profit
FY2025Q1
YoY :
-27.29%
-3.35M
Net Income after Tax
FY2025Q1
YoY :
-35.29%
-0.22
EPS - Diluted
FY2025Q1
YoY :
-54.44%
-1.99M
Free Cash Flow
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
INTS News & Events
Events Timeline
2025-06-30 (ET)
2025-06-30
08:06:08
Intensity Therapeutics: INT230-6 achieved 100% complete response rate in MPNST

2025-06-12 (ET)
2025-06-12
05:55:01
Intensity Therapeutics 6.675M share Spot Secondary priced at 30c

2025-06-11 (ET)
2025-06-11
16:12:46
Intensity Therapeutics announces common stock offering, no amount given

Sign Up For More Events
Sign Up For More Events
News
5.0
06-30PRnewswireOncology Innovation Just Hit a Turning Point -- Here's What to Watch
9.0
06-30PRnewswireIntensity Therapeutics, Inc. Announces that INT230-6 Achieved 100% Complete Response Rate in Preclinical Models of Malignant Peripheral Nerve Sheath Tumors (MPNST)
5.0
06-20NewsfilterWith Public Funding Under Pressure, Biotech Innovators Are Picking Up the Slack in Oncology
Sign Up For More News
People Also Watch

DXR
Daxor Corp
10.144
USD
+1.44%

TOI
Oncology Institute Inc
3.680
USD
+0.82%

ANEB
Anebulo Pharmaceuticals Inc
3.190
USD
-1.54%

BRFH
Barfresh Food Group Inc
3.080
USD
+1.65%

YOTA
Yotta Acquisition Corp
11.200
USD
+6.35%

CALC
CalciMedica Inc
3.800
USD
+2.98%

VIVK
Vivakor Inc
0.920
USD
+14.29%

MDAI
Spectral AI Inc
2.600
USD
-4.06%

IZEA
IZEA Worldwide Inc
3.940
USD
-3.90%

HKIT
Hitek Global Inc
1.400
USD
+1.08%
FAQ

What is Intensity Therapeutics Inc (INTS) stock price today?
The current price of INTS is 0.325 USD — it has increased 0 % in the last trading day.

What is Intensity Therapeutics Inc (INTS)'s business?

What is the price predicton of INTS Stock?

What is Intensity Therapeutics Inc (INTS)'s revenue for the last quarter?

What is Intensity Therapeutics Inc (INTS)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Intensity Therapeutics Inc (INTS)'s fundamentals?

How many employees does Intensity Therapeutics Inc (INTS). have?
